The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Sanofi SA (NASDAQ:SNY) reported Thursday a first-quarter 2025 business operating income of 2.9 billion euros ($3.06 billion), ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Sanofi (SNY) stock and Roche (RHHBY) stock trade flat after the duo reaffirmed 2025 forecasts despite strong Q1 results. Read ...

Sanofi confirms the expectation of a strong rebound in business EPS with growth at a low double-digit percentage at CER (before share buyback)6 • Sanofi intends to complete a share buyback program in ...

France's Sanofi reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its ...

Sanofi: strong Q1 performance and 2025 guidance confirmed Paris, April 24, 2025 Q1 sales growth of 9.7% at CER1 and business EPS2 of €1.79 Pharma launches reached sales of €0.8 billion, up 43.8%, ...

--U.S. FDA Delays: Sanofi is potentially exposed to any delays in reviews due to recently announced staff firings at the U.S. Food and Drug Administration. Its anti-inflammatory drug Dupixent was ...

Mark Esser, an executive at Big Pharma firm AstraZeneca, has been named the inaugural leader of UVa's future Manning ...

Some market observers point to stronger efficacy data with Beyfortus than Pfizer’s shot, particularly on severe disease, as well as clinician familiarity with use of antibodies. That could drive ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click ...